Heyman Richard A.
- SEC CIK
- 0001584759
In the past year, 6 open-market sale filings worth $654.9K and no purchases.
Current role at each company
- ORIC Oric Pharmaceuticals, Inc.Directoras of Jul 28, 2026
- ELVN Enliven Therapeutics, Inc.Directoras of Feb 19, 2026
- PMVP PMV Pharmaceuticals, Inc.Directoras of Jun 9, 2025
- RYZB RayzeBio, Inc.Directoras of Feb 27, 2024
- MTCR Metacrine, Inc.Directoras of Sep 6, 2022
Show 1 more company
- GRTS Gritstone bio, Inc.Directoras of Jun 22, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $654.9K
- 6 filings
- Net
- −$654.9K
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists Heyman Richard A. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ORIC Oric Pharmaceuticals, Inc.
Director8 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2021 (view filing) | Sep 7 | 2 days | Heyman Richard A.Director | SSale | −1.09K | $25.11 | −$27.3K | −0.5%218.7K after | |
| Sep 14, 2021 (view filing) | Sep 10-13 | 4 days | Heyman Richard A.Director | SSale | −1.08K | $25.05 | −$27.1K | −0.5%217.7K after | 2 lots |
| Sep 16, 2021 (view filing) | Sep 14-15 | 2 days | Heyman Richard A.Director | SSale | −1.39K | $25.04 | −$34.8K | −0.6%216.3K after | 2 lots |
| Jan 20, 2026 (view filing) | Jan 16 | 4 days | Heyman Richard A.Director | SSale | −3.50K | $12.00 | −$42.0K | −7.7%41.8K after | 10b5-1 |
| Jan 20, 2026 (view filing) | Jan 16 | 4 days | Heyman Richard A.Director | SSale | −3.20K | $12.00 | −$38.4K | −1.5%213.1K after | 10b5-1 |
| Jul 8, 2026 (view filing)4:35 PM ET | Jul 6 | 2 days | Heyman Richard A.Director | SSale | −300 | $12.00 | −$3.60K | −0.1%212.8K after | 10b5-1 |
| Jul 28, 2026 (view filing)4:15 PM ET | Jul 24 | 4 days | Heyman Richard A.Director | SSale | −7.00K | $12.02 | −$84.1K | −15.5%38.3K after | 10b5-1 |
| Jul 28, 2026 (view filing)4:15 PM ET | Jul 24 | 4 days | Heyman Richard A.Director | SSale | −6.10K | $12.02 | −$73.3K | −2.9%206.7K after | 10b5-1 |
ELVN Enliven Therapeutics, Inc.
Director24 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 21, 2023 (view filing) | Dec 19-20 | 2 days | Heyman Richard A.Director | SSale | −2.37K | $13.02 | −$30.8K | −1.6%147.5K after | 2 lots10b5-1 |
| Dec 21, 2023 (view filing) | Dec 20 | 1 day | Heyman Richard A.Director | SSale | −1.92K | $13.02 | −$24.9K | −6.1%29.3K after | 10b5-1 |
| Dec 26, 2023 (view filing) | Dec 21-22 | 5 days | Heyman Richard A.Director | SSale | −175 | $13.00 | −$2.27K | −0.1%147.3K after | 2 lots10b5-1 |
| Dec 26, 2023 (view filing) | Dec 21-22 | 5 days | Heyman Richard A.Director | SSale | −41 | $13.00 | −$533 | −0.1%29.2K after | 2 lots10b5-1 |
| Feb 1, 2024 (view filing) | Jan 30 | 2 days | Heyman Richard A.Director | SSale | −1.27K | $16.41 | −$20.8K | −0.9%146.0K after | 10b5-1 |
| Feb 20, 2024 (view filing) | Feb 15 | 5 days | Heyman Richard A.Director | SSale | −1.27K | $17.42 | −$22.1K | −0.9%144.7K after | 10b5-1 |
| Mar 21, 2024 (view filing) | Mar 19 | 2 days | Heyman Richard A.Director | SSale | −1.27K | $14.50 | −$18.4K | −0.9%143.5K after | 10b5-1 |
| Apr 15, 2024 (view filing) | Apr 11-15 | 4 days | Heyman Richard A.Director | SSale | −6.32K | $24.02 | −$151.7K | −4.4%137.2K after | 3 lots10b5-1 |
| Apr 15, 2024 (view filing) | Apr 11 | 4 days | Heyman Richard A.Director | SSale | −649 | $25.00 | −$16.2K | −2.2%28.6K after | 10b5-1 |
| May 20, 2024 (view filing) | May 16 | 4 days | Heyman Richard A.Director | SSale | −1.27K | $23.74 | −$30.1K | −0.9%135.9K after | 10b5-1 |